Iruxol Mono

Collagenase Clostridium Histolyticum, the active ingredient in Iruxol, is a proteolytic enzyme presented as a topical formulation for cutaneous use. It enzymatically debrides necrotic tissue, facilitating wound healing in chronic wounds, pressure ulcers, diabetic foot ulcers, burns and traumatic skin lesions.

GNH USA supplies Iruxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable logistics, technical support, and compliance documentation.

Iruxol Mono, a collagenase enzyme, is used for enzymatic debridement of necrotic tissue in various wound types.

- Chronic wounds: removal of necrotic tissue to promote granulation and healing. - Pressure ulcers: enzymatic breakdown of dead tissue to accelerate recovery. - Diabetic foot ulcers: facilitates debridement, supporting ulcer management. - Burns: assists in clearing eschar and necrotic layers for better regeneration. - Traumatic skin lesions: aids in selective removal of damaged tissue while preserving viable cells.

Local application of Iruxol may cause reactions at the treatment site.

Common Side Effects: - Redness or erythema at the application site. - Mild pain or burning sensation. - Swelling or edema. - Itching or pruritus. - Slight bleeding or oozing. - Increased wound exudate.

Serious or Rare Side Effects: - Severe allergic reaction, including rash or hives. - Anaphylaxis requiring emergency care. - Cellulitis or secondary infection. - Deep tissue necrosis beyond intended area. - Systemic infection signs such as fever. - Persistent severe pain.

When using Iruxol, consider the following safety measures. - Assess wound suitability: ensure presence of necrotic tissue and no active infection. - Avoid use on healthy tissue: limit application to debridement areas only. - Monitor for local irritation: discontinue if severe redness or pain occurs. - Do not apply under occlusive dressings unless directed by a clinician. - Store at room temperature: keep in the original container, protect from moisture and light.

Iruxol may interact with other agents applied to the wound.

Major Interactions (Avoid): - Concurrent use with other proteolytic enzymes: may increase tissue damage. - Use with systemic antibiotics: no direct interaction but monitor infection status. - Co‑administration with immunosuppressants: may impair wound healing.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may reduce enzyme activity and effectiveness. - Anticoagulants: increased risk of bleeding at the application site.